Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

rucaparib 300 MG Oral Tablet

Known as: RUCAPARIB 300MG TAB, RUCAPARIB 300MG TAB [VA Product], rucaparib (as rucaparib camsylate) 300 MG Oral Tablet 
 
National Institutes of Health

Related topics

Related topics

3 relations
Oral TabletPoly(ADP-Ribose) Polymerase Inhibitors [MoA]rucaparib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
Rucaparib camsylate (CO-338, AG-014699, PF-01367338) is a potent PARP-1, PARP-2, and PARP-3 inhibitor. Phase I and II studies… Expand
  • figure 1
  • table 1
  • figure 2
Review
2016
Review
2016
Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.
Rucaparib camsylate (CO-338; 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE